Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

NCT02125877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Iron Overload Due to Transfusion-dependant Anemias

Interventions

DRUG: Deferasirox dispersible tablet
DRUG: Defearisox film-coated tablet

Sponsor

Novartis Pharmaceuticals